Inhibikase Therapeutics, Inc 8-K, filed Oct 20, 2026
Inhibikase Therapeutics, Inc. (IKT)
About this 8-K
Inhibikase Therapeutics, Inc filed this 8-K on October 20, 2026, reporting on events of October 19, 2026.
Inhibikase Therapeutics said Dennis Berman resigned from its board and committee roles effective October 19, 2026. The board appointed Scott Wasserman as a Class III director the same day, with options to purchase up to 310,000 shares. AI summary
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Resignation of Dennis Berman
On October 19, 2026, Dennis Berman resigned from the board of directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) and his position as Chair of the Compensation Committee of the Board (the “Compensation Committee”) and a member of the Audit Committee of the Board (the “Audit Committee”), effective as of October 19, 2026. Mr. Berman advised the Company that his decision to resign was not the result of any disagreement with the Company or its management on any matter relating to the Company’s operations, policies or practices.
Appointment of Scott Wasserman
On October 19, 2026, the Board, upon the recommendation of the Board’s Corporate Governance and Nominating Committee, appointed Scott Wasserman to serve as a Class III director, to hold office until the Company’s annual meeting of stockholders in 2029 or until his earlier death, resignation or removal, effective as of October 19, 2026 (the “Appointment Date”). In addition, Dr. Wasserman will serve as a member of the Compensation Committee. The Board has determined that Dr. Wasserman is independent under the applicable listing standards of The Nasdaq Stock Market LLC and the rules and regulations of the Securities and Exchange Commission.
In connection with his appointment to the Board, Dr. Wasserman will receive an initial new director grant of non-qualified stock options to purchase up to 310,000 shares of the Company’s common stock, and cash compensation for his Board and committee service, in accordance with the Company’s Non-Employee Director Compensation Policy, as such policy may be amended from time to time.
There are no arrangements or understandings between Dr. Wasserman and any other person pursuant to which he was selected to serve on the Board. There are no transactions in which the Company or any of its subsidiaries is a party and in which Dr. Wasserman has a material interest subject to disclosure under Item 404(a) of Regulation S-K. In addition, Dr. Wasserman entered into an indemnification agreement with the Company consistent with the form of indemnification agreement, a copy of which has been previously filed with the Company’s most recent Annual Report on Form 10-K.
| Item 7.01. | Regulation FD Disclosure. |
On October 20, 2026, the Company issued a press release titled “Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors.” A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| 99.1 | Press Release issued by Inhibikase Therapeutics, Inc., dated October 20, 2026, furnished herewith. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 20, 2026 | INHIBIKASE THERAPEUTICS, INC. | |||||
| By: | /s/ Mark Iwicki | |||||
| Mark Iwicki | ||||||
| Chief Executive Officer | ||||||
Exhibit 99.1
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
WILMINGTON, Del., October 20, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman’s appointment, the Company also announced the resignation of Dennis Berman from the Company’s Board. “We thank Dennis for his many contributions to the Company during his years of service” said Amit Munshi, Chair of the Inhibikase Board of Directors.
Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions. Dr. Wasserman is a cardiologist with more than two decades of experience in clinical development and company leadership. At Amgen Inc., he served as Vice President, Global Development and Therapeutic Area Head for Bone, Cardiovascular, Metabolic and Neuroscience. He was Amgen’s first cardiologist and built the company’s cardiovascular and metabolic strategy, team and portfolio. He led the global development and approvals of Repatha (evolocumab), was instrumental in the development and U.S. FDA approval of Evenity (romosozumab) and oversaw the U.S. approval of Aimovig (erenumab).
“Scott has taken multiple programs from early development through global approval, and he has built clinical organizations at both large and emerging companies,” said Amit Munshi. “We look forward to benefiting from his expertise as we continue to advance our global Phase 3 IMPROVE-PAH study of IKT-001. We are pleased to welcome Scott to our Board.
“PAH is a progressive, life-threatening disease, and the pedigree of imatinib together with the recent preclinical and Phase 1 data for IKT-001 point to a very promising role for this asset in this difficult to treat condition,” said Dr. Wasserman. “This is an important time for Inhibikase, and I look forward to applying my experience in global clinical development and regulatory interactions as the Company advances IMPROVE-PAH.”
Scott brings deep expertise in clinical development to Inhibikase’s Board of Directors, spanning global development strategy, clinical trial design and execution, and global regulatory interactions. Most recently, Scott served as Venture Partner at Frazier Life Sciences, focusing on company creation. Prior to Frazier, Scott was the CEO and co-founder of Latigo Biotherapeutics, a venture-backed biotechnology company developing first and best-in-class, non-opioid pain medicines. Prior to his role with Latigo, Scott was Vice President, Global Development Therapeutic Area Head for Bone, Cardiovascular, Metabolic, and Neuroscience at Amgen. In addition to his role in the development of Repatha, Evenity, and Aimovig, Scott oversaw therapeutic development for a range of other conditions, including heart failure, anemia, obesity, and Alzheimer’s disease.
Prior to joining industry, Scott was on faculty at Stanford University in the Division of Cardiovascular Medicine conducting NIH-sponsored research on endothelial gene expression and served as a non-interventional cardiologist at the Veterans Administration Hospital in Palo Alto, CA. Scott received his BS, Magna Cum Laude from Haverford College and his MD, Magna Cum Laude from Harvard Medical School. He completed his postgraduate training in Internal Medicine and Cardiovascular Medicine at Stanford University and post-doctoral cardiovascular research at COR Therapeutics, Millennium Pharmaceuticals, and Stanford.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.
Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential of IKT-001, the advancement of the IMPROVE-PAH study, and the anticipated contribution of Dr. Wasserman to the Company’s board of directors. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com